Abstract: The use of inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) in the treatment of cancer is disclosed. In preferred embodiments, the Myt1 inhibitor is a carboxamide pyrrolopyrazine or carboxamide pyrrolopyridine of Formula I. The Myt1 inhibitors may be used in combination with a variety of other anti-cancer agents. Such agents include a WEE1 inhibitor, TOPI or TOP2A inhibitor, RRM1 or RRM2 inhibitor, AURKA or AURKB inhibitor, ATR inhibitor, TTK inhibitor, SOD1 or SOD2 inhibitor, BUB1 inhibitor, CDC7 inhibitor, SAE1 inhibitor, PLK1 inhibitor, UBA2 inhibitor, DUT inhibitor, HDAC3 inhibitor, CHEK1 inhibitor, MEN1 inhibitor, DOT1L inhibitor, CREBBP inhibitor, EZH2 inhibitor, PLK4 inhibitor, HASPIN inhibitor, METTL3 inhibitor, nucleoside analogs, and platinum-based DNA alkylating agents.

Abstract: Disclosed are methods of using inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1), e.g., in the treatment of subjects in need thereof.